Big Moving Stock keep track of the biggest moving stocks in the market.
The Hot Industries
Asset Management 2
The Hot Sectors
AMRN Amarin Corporation plc
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases in the United States. It develops products in the areas of lipid science and therapeutic benefits of polyunsaturated fatty acids. The company markets Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It is also developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.
Amarin Corporation plc (AMRN) in Focus: Stock Soars 23.4% - Tale of the Tape19 Nov 2014, 8:58 amAmarin Corporation plc (AMRN) in Focus: Stock Soars 23.4% - Tale of the Tape
Amarin Corporation plc (AMRN) in Focus: Stock Soars 23.4%19 Nov 2014, 4:12 amAmarin Corporation plc (AMRN) was a big mover last session, as the company saw its shares rise by over 23% on the day.
Amarin up again today on Vascepa data18 Nov 2014, 9:47 amAmarin ( AMRN +22.4% ) is up again today on a 50% increase in volume as money flows into the stock in response to a presentation of new data and analyses from the Marine and Anchor Phase 3 Vascepa (icosapent ethyl) trials. Shares are now up 54% from the low of $0.78 on November 11.
Biotech Stock Mailbag: Spectrum, Intercept, Orexigen, Amarin, MannKind14 Nov 2014, 4:47 pmBiotech columnist Adam Feuerstein answers readers' questions about health care. Click to view a price quote on ICPT . Click to research the Drugs industry.
Amarin Reports Third Quarter 2014 Financial Results and Provides Update on Operations6 Nov 2014, 2:00 pmAmarin Corporation plc , a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the three ...
MTNB: Initiating Coverage On Matinas BioPharma - A New Player In The Fish Oil Market30 Oct 2014, 8:00 amMatinas is developing MAT9001, a proprietary prescription grade omega-3 fatty acid composition, comprised of a complex mixture of omega-3 fatty acids, predominantly eicosapentaenoic acid (“EPA”), and docosapentaenoic acid (“DPA”), a rare and potent omega-3 fatty acid. The product also contains several other omega-3 fatty acids, including relatively small amounts of docosahexaenoic acid (“DHA ...